Literature DB >> 22762727

Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study.

Emanuela Lapice1, Paola Cipriano, Lidia Patti, Geremia Romano, Olga Vaccaro, Angela A Rivellese.   

Abstract

OBJECTIVE: To test whether there is an association between fasting ApoB48 level, a marker of the residual presence of intestinally derived TRLs lipoproteins, thought to be highly atherogenic, and peripheral artery disease (PAD) in type 2 diabetic patients independent of fasting plasma lipids.
METHODS: We studied 87 patients with type 2 diabetes: 34 with asymptomatic PAD (ankle/brachial index < 0.9) and 53 without PAD matched on age (±2 years), gender and BMI (±2 kg/m(2)). The plasma fasting ApoB48 was measured by ELISA.
RESULTS: Patients with PAD had significantly higher ApoB48 levels (1.529 ± 1.253 vs 1.095 ± 0.667 μg/ml p = 0.04) than those without PAD independent of major confounders, such as duration of diabetes, smoking status, HbA1c, systolic blood pressure and fasting plasma lipids.
CONCLUSIONS: Fasting ApoB48 was independently associated with asymptomatic PAD in patients with type 2 diabetes.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762727     DOI: 10.1016/j.atherosclerosis.2012.05.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

Review 2.  Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link?

Authors:  Pedro Valdivielso; José Ramírez-Bollero; Carmen Pérez-López
Journal:  World J Diabetes       Date:  2014-10-15

Review 3.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

4.  Effects of a 1-year randomised controlled trial of resistance training on blood lipid profile and chylomicron concentration in older men.

Authors:  Anthony P James; Joanna Whiteford; Timothy R Ackland; Satvinder S Dhaliwal; Jenni J Woodhouse; Richard L Prince; Xingqiong Meng; Deborah A Kerr
Journal:  Eur J Appl Physiol       Date:  2016-09-02       Impact factor: 3.078

5.  Fasting apolipoprotein B48 is associated with large artery atherosclerotic stroke: a case-control study.

Authors:  Jing Tian; Hong Chen; Ping Liu; Chun Wang; Yong Chen
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

6.  Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.

Authors:  Takeshi Onoue; Motomitsu Goto; Eri Wada; Mariko Furukawa; Takayuki Okuji; Norio Okada; Tomoko Kobayashi; Shintaro Iwama; Mariko Sugiyama; Taku Tsunekawa; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Yoshiaki Morishita; Yusuke Seino; Hidetaka Suga; Ryoichi Banno; Yoji Hamada; Masahiko Ando; Etsuko Yamamori; Hiroshi Arima
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.